Effects of N-Acetylcysteine on Nicotinamide Dinucleotide Phosphate Oxidase Activation and Antioxidant Status in Heart, Lung, Liver and Kidney in Streptozotocin-Induced Diabetic Rats

Shaoqing Lei,1,2 Yanan Liu,2 Huimin Liu,2 Hong Yu,3 Hui Wang,1 and Zhengyuan Xia1,2

1Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan; 2Department of Anesthesiology, The University of Hong Kong, Hong Kong SAR; 3Department of Biochemistry and Molecular Biology, School of Basic Medical Science, Wuhan University, Wuhan, China.

Purpose: Hyperglycemia increases reactive oxygen species (ROS) and the resulting oxidative stress plays a key role in the pathogenesis of diabetic complications. Nicotinamide dinucleotide phosphate (NADPH) oxidase is one of the major sources of ROS production in diabetes. We, therefore, examined the possibility that NADPH oxidase activation is increased in various tissues, and that the antioxidant N-acetylcysteine (NAC) may have tissue specific effects on NADPH oxidase and tissue antioxidant status in diabetes.

Materials and Methods: Control (C) and streptozotocin-induced diabetic (D) rats were treated either with NAC (1.5 g/kg/day) orally or placebo for 4 weeks. The plasma, heart, lung, liver, kidney were harvested immediately and stored for biochemical or immunoblot analysis.

Results: levels of free 15-F₂-isoprostane were increased in plasma, heart, lung, liver and kidney tissues in diabetic rats, accompanied with significantly increased membrane translocation of the NADPH oxidase subunit p67phox in all tissues and increased expression of the membrane-bound subunit p22phox in heart, lung and kidney. The tissue antioxidant activity in lung, liver and kidney was decreased in diabetic rats, while it was increased in heart tissue. NAC reduced the expression of p22phox and p67phox, suppressed p67phox membrane translocation, and reduced free 15-F₂-isoprostane levels in all tissues. NAC increased antioxidant activity in liver and lung, but did not significantly affect antioxidant activity in heart and kidney.

Conclusion: The current study shows that NAC inhibits NADPH oxidase activity in diabetes and attenuates tissue oxidative damage in all organs, even though its effects on antioxidant activity are tissue specific.

Key Words: Antioxidant status, diabetes, 15-F₂-isoprostane, N-acetylcysteine, NADPH oxidase

INTRODUCTION

Diabetes mellitus is a serious metabolic disease, and the number of people with diabetes is rapidly increasing due to population growth, aging, urbanization, and in-
creasing prevalence of obesity. Hyperglycaemia-induced oxidative stress, as a result of excessive production of reactive oxygen species (ROS), plays a key role in the pathogenesis of diabetes-related complications. Theoretically, suppression of oxidative stress using antioxidants should reverse adverse effects induced by hyperglycaemia in diabetic patients. However, large randomized clinical trials have failed to provide convincing evidence for effective antioxidant therapy with classic antioxidants, such as vitamins E and C. Therefore, development of new therapeutic regimes is important for patients with diabetes.

Oxidative stress results from increased production of ROS or diminished antioxidant capacity in cells or tissues. One of the major sources of ROS in tissues of diabetic patients is nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. NADPH oxidase contains two membrane-bound subunits gp91phox (Nox2) and p22phox and cytoplasmic subunits such as p47phox, p67phox and a low-molecular-weight G protein (rac 1 and rac 2). NADPH oxidase catalyzes the generation of superoxide anion using NADPH as the electron donor in cells. Superoxide is well known to be a mediator of inflammation and an inducer of apoptosis. Expression or activation of NADPH oxidase is increased in diabetes or high-glucose treated endothelial cells. We previously showed that long term treatment with the antioxidant N-acetylcysteine (NAC) could inhibit NADPH oxidase activation in the heart of diabetic rats, and it also abolished the compensatory increase in the antioxidant enzyme superoxide dismutase (SOD). It is, however, unknown whether or not short term NAC treatment may preserve the compensatory increase of endogenous SOD protein expression in diabetes, while maintaining its inhibitory effects on NADPH oxidase activation.

SOD, including cytosolic Cu/Zn-SOD, mitochondrial Mn-SOD and extracellular SOD, are enzymes involved in the scavenging of superoxide anions and play an important role in balancing ROS generation. Superoxide anions are mainly generated by the mitochondrial electron transport chain and are implicated in the progression of diabetes. Increased ROS production in diabetes can be prevented by the administration of SOD. A recent study showed that total SOD activity and extracellular Cu/Zn-SOD activity were reduced, whereas Mn-SOD activity was increased in the heart of long-term diabetic rats. This indicates that individual endogenous tissue antioxidant enzymes and potentially the total tissue antioxidant activity may change differently in diabetes. This complexity may potentially affect the effectiveness of antioxidant therapies. During early diabetes, various tissues may enhance their antioxidant enzymes activity to withstand hyperglycaemia-induced ROS production. However, little is known regarding the tissue specific changes of overall antioxidant capacity and the underlying mechanism in early diabetes.

We hypothesized that changes in the levels of both NADPH oxidase and SOD may be tissue specific, possibly having a significant impact on the total tissue antioxidant activity and on the effectiveness of antioxidant treatment in early diabetes. Therefore, this hypothesis was tested in an established rat model of STZ-induced type 1 diabetes. Since glutathione (GSH) depletion may play an important role in the development of diabetic complications and GSH depletion occurs in early diabetes, we also explored the treatment effects of N-acetylcystein, a GSH precursor that can enhance the GSH antioxidant defense.

**MATERIALS AND METHODS**

**Experiment design and induction of diabetes**

Sprague-Dawley male rats aged 8 weeks and weighing 250 to 280 gram were purchased from the Animal Unit of Wuhhan University, China, and allowed to adapt in their cages for three days before experiments. All rats had free access to standard chow and water. The experiments were performed in accordance with our institutional animal care guidelines which are in line with the use of Laboratory Animals published by the US National Institutes of Health. The study was approved by Institutional Animal Care and Use Committee.

Diabetes was induced by a single tail vein injection (under halothane anaesthesia) of streptozotocin (Sigma, St. Louis, MO, USA) (STZ, 60 mg/kg body weight, freshly dissolved in 0.1 M citrate buffer, pH 4.5), while control rats (n=7) were injected equal volume citrate buffer alone. Three days following STZ injection, blood glucose levels were measured using a Glucose Analyzer (Beckman Instruments, Fullerton, CA, USA), and rats with hyperglycaemia (set at plasma glucose ≥16.7 mM) were used for the experiments.

NAC, at the dose of 1.5 g/kg/day, had no effects on NADPH oxidase activity and SOD activity in non-diabetic control rats but had effects on these parameters in diabetic rats. In the current study, therefore, NAC was used only in diabetic rats. One week after the induction of diabetes, rats were randomly assigned into NAC-treated or untreated groups.
(n=7, per group), and they were treated respectively with the antioxidant NAC (1.5 g/kg/day, D+NAC) or an equal volume of 0.9% saline (D) delivered by oral gavage. Rats in the non-diabetic control group (C) were treated also with an equal volume of 0.9% saline delivered by oral gavage. Treatments in all groups were continued for four weeks.

**Plasma and tissue preparations**

At the end of four weeks of treatment, the rats were anti-coagulated with heparin (1000 IU/kg) and then anaesthetized with pentobarbital sodium (65 mg/kg body weight). Blood glucose level and body weight were measured by a Glucose Analyzer (Beckman Instruments, Fullerton, CA, USA) and a lab scale, respectively. Blood samples were collected in heparinized syringes by heart puncture after opening the thoracic cavity. The collected blood was immediately centrifuged at 3000×g, plasma separated, aliquoted into small microcentrifuge tubes, and stored at -80°C for further detection. Heart, kidney, liver and lung tissues were harvested immediately after sacrifice and frozen in liquid nitrogen and stored at -80°C for further experiments.

**Inflammatory cytokines in plasma**

Plasma levels of inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 were measured, using the commercially available rat ELISA kit (Bender Med, Vienna, Austria) according to the manufacturer’s instructions.

**Enzyme immunoassay (EIA) for free 15-F_2t-isoprostane**

15-F₂-isoprostane (15-F₂-Isop), a specific marker of oxidative stress, was measured using an EIA kit (Cayman chemical, Ann Arbor, MI, USA). Thus, plasma samples or homogenized heart tissue (in PBS) were purified using Affinity Sorbent/Column (Cayman chemical, Ann Arbor, MI, USA) in the presence of 0.01% butylated hydroxytoluene and then processed for analysis of free 15-F₂-Isop as described. The values of plasma or tissue 15-F₂-Isop were expressed as pg/mL in plasma or pg/mg protein in tissue homogenates.

**Total antioxidant activity determination**

Tissue sections (50 mg) were homogenized in 1 mL of cold buffer (5 mM potassium phosphate, pH 7.4, containing 0.9% sodium chloride and 0.1% glucose) and were centrifuged at 10000×g for 15 min at 4°C. The supernatant was collected for assay. Total antioxidant activity in plasma and tissue homogenate was measured using the Total Antioxidant Status Assay Kit (Calbiochem, Darmstadt, Germany), which is dependent on the capacity in the sample to inhibit the oxidation of ABTS⁺-[2,2’-Azino-di-(3-ethylbenz-thiazoline sulphonate)] to ABTS⁺⁺ by metmyoglobin (a peroxidase). The amount of ABTS⁺⁺ produced can be monitored by reading absorbance at 600 nm. Under the reaction conditions used, the antioxidants in the sample suppress absorbance at 600 nm by the degree proportional to their concentration. Total antioxidant activity was calculated and expressed as millimole per liter (mM) in plasma or millimole per gram protein in tissue samples (mmol/g protein).

**Total superoxide dismutase activity assay**

SOD activity was determined using a Superoxide Dismutase Assay Kit (Cayman chemical, Ann Arbor, MI, USA) following the manufacturer’s instructions. Plasma samples were assayed immediately after being thawed. Tissue sections (50 mg) were homogenized in 1 mL of cold 20 mM HEPES buffer, pH 7.2, containing 1 mM EGTA, 210 mM mannitol and 70 mM sucrose, and centrifuged at 1500×g for 5 min at 4°C, and the supernatants were collected for assay. The assay utilizes a tetrazolium salt for detection of superoxide radicals generated by xanthine oxidase and hapoxanthine. One unit of SOD is defined as the amount of enzyme needed to exhibit 50% dismutation of the superoxide radical. SOD activity was calculated and expressed as units per milliliter (U/mL) in plasma or units per milligram protein (U/mg protein) in tissue preparations.

**Tissue sample preparations and western blot analysis**

In order to characterize subcellular distribution of targeted proteins, tissue samples were processed to isolate membrane and cytosolic fractions as previously described. Briefly, 150 mg of heart, lung, kidney and liver tissue samples were pulverized separately with mortar and pestle in liquid nitrogen, and then homogenized using a Polytron homogenizer in 1.5 mL of cold buffer A, which contained (in mM) 5 Tris-HCl (pH 7.5), 5 MgCl₂, 10 EGTA, 2 EDTA, 1 NaHCO₃, 1 PMSF, 1 β-glycerophosphate, 1 NaF, 1 NaVO₃, and (in μg/mL) 20 leupeptin and 4 aprotinin. The homogenate was centrifuged at 10000×g for 10 min at 4°C. The supernatant was collected and used as total tissue extracts. The supernatant was then further centrifuged at 100000×g for 60 min at 4°C. The supernatant was removed as cytosol fractions. The pellets were resuspended in buffer B containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 10% glycerol, 1 mM PMSF, 1 mM β-glycerophosphate, 60 mM glycerol, 1 mM PMSF, 1 mM β-glycerophosphate, 60 mM...
Octyl β-glucopyranoside, 1 mM NaF, 0.1 mM Na3VO4, and (in μg/mL) 20 leupeptin and 4 aprotinin. The suspensions were homogenized again, held on ice for 30 min, and centrifuged at 10000×g for 60 min at 4°C. The supernatant was collected as membrane fractions. The proteins from each fraction (50-100 μg) were resolved via SDS-PAGE and subsequently transferred to PVDF membrane for immunoblot analysis. The membranes were blocked in 5% non-fat milk for 2 h at room temperature, washed three times with TBS-T buffer each for 5 min, and then incubated overnight at 4°C with primary antibodies raised against Cu/Zn-SOD (rabbit antiserum), Mn-SOD (rabbit polyclonal IgG) (1 : 1000, Millipore Corporation), p22phox and p67phox (rabbit polyclonal antibody, 1 : 500, Santa Cruz Biotechnology), respectively. After washing three times with TBS-T for 30 min, the blot was incubated for 1 h at room temperature with anti-rabbit IgG, HRP-linked antibody (1 : 10000, Cell Signaling). After washing the membranes, the blot was developed with enhanced chemiluminescence reagent (GE Healthcare) and then exposed to X-ray film. The same blot was stripped and rebotted with antibodies to ward GAPDH (1 : 2000, Cell Signaling) in total tissue extracts and cytosol fractions, or Na, K-ATPase (1 : 2000, Cell Signaling) in membrane fractions as an internal control. The intensity of the bands was quantified using image analysis software (Bio-Rad, Hercules, CA, USA), and the results were normalized to corresponding internal controls to correct for loading. Data are presented as percent change relative to the measurement in control rats.

Statistical analysis
The values are presented as mean±S.E.M. All biochemical assays were performed in duplicate and averaged before being analyzed. One-way or two-way analysis of variance was used for statistical analyses of data obtained within the same group and between groups, respectively. Tukey’s test was used for multiple comparisons of group means. Significance was defined as p<0.05.

RESULTS

General characteristics and effects of NAC treatment
Administration of STZ resulted in characteristic symptoms of diabetes including hyperglycemia, and reduced body weight gain along with increased food and fluid intake when compared to age-matched controls (Table 1). Food consumption, water intake and plasma glucose levels in the diabetic group were much higher than those in the age-matched control group (p<0.01). NAC treatment significantly reduced water intake and food consumption compared with the diabetic untreated group (p<0.05), but did not significantly affect glucose levels. Body weight in the diabetic group was lower than that of the control group (p<0.05), and NAC treatment did not have significant effects on body weight gain (Table 1).

Table 1. General Characteristics of Rats at the End of the Study

|               | Control (C) | Diabetic (D) | D+NAC       |
|---------------|-------------|--------------|-------------|
| Food consumption (g/kg/day) | 65.0±1.5 | 191.4±4.1* | 146.2±3.7* |
| Water intake (mL/kg/day) | 120.0±7.6 | 831.5±11.3* | 423.8±8.5* |
| Body weight (g) | 490.7±14.5 | 312.4±19.4* | 305.8±13.3* |
| Plasma glucose (mM) | 6.3±0.7 | 27.1±1.5* | 25.9±1.3* |

Control (C) or streptozotocin-induced diabetic rats were either untreated (D) or treated with the antioxidant N-acetylcysteine (1.5 g/kg/day, D+NAC) by oral gavage for four weeks. All values are expressed as means±S.E.M., n=7.
* p<0.05 compared with control group.
† p=0.05 compared with diabetic group.

Table 2. Inflammatory Cytokines at the End of the Study

|               | Control (C) | Diabetic (D) | D+NAC       |
|---------------|-------------|--------------|-------------|
| Plasma TNF-alpha (pg/mL) | 18.5±1.1 | 41.2±5.5* | 20.3±2.5* |
| Plasma IL-6 (pg/mL) | 42.7±2.7 | 58.0±2.4* | 44.7±4.2* |

TNF, tumor necrosis factor; IL, interleukin. Control (C) or streptozotocin-induced diabetic rats were either untreated (D) or treated with the antioxidant N-acetylcysteine (1.5 g/kg/day, D+NAC) by oral gavage for four weeks. All values are expressed as means±S.E.M., n=7.
* p<0.05 compared with control group.
† p<0.05 compared with diabetic group.
Inflammatory disorder
Diabetes is associated with disorders of many inflammatory cytokines. As shown in Table 2, the plasma levels of TNF-alpha and IL-6 in diabetic rats were increased significantly as compared to control rats ($p<0.05$), which were prevented by treatment with NAC.

Oxidative stress marker: free 15-F$_{2}$t-IsoP levels in plasma and tissue
Plasma (Fig. 1A) and tissue (Fig. 1B) levels of free 15-F$_{2}$t-IsoP in the diabetic group were much higher than those in the control group (all $p<0.05$ or $p<0.01$). NAC treatment significantly reduced free 15-F$_{2}$t-IsoP concentrations in the plasma and prevented the significant increase of 15-F$_{2}$t-IsoP in the heart, lung and liver tissues seen in the diabetic group (all $p<0.05$, D+NAC vs. D). NAC significantly reduced, but did not normalize 15-F$_{2}$t-IsoP levels in the kidney ($p<0.05$, D+NAC vs. D; $p<0.05$, D+NAC vs. C) (Fig. 1B).

Total antioxidant activity in plasma and various tissues
Total antioxidant activity represents the total antioxidant capacity in tissues or in the plasma. Plasma total antioxidant activity in diabetic rats was higher than that of the control group ($p<0.01$) (Fig. 2A). NAC treatment significantly attenuated this increase in plasma total antioxidant levels in diabetic rats ($p<0.05$, D+NAC vs. D) (Fig. 2A). Changes in tissue total antioxidant activity and the effects of NAC treatment were tissue-specific. The total antioxidant activity in the heart in the diabetic group was higher than that in the control group ($p<0.05$) and was unaffected by NAC treatment (Fig. 2B). In contrast, however, total antioxidant activity in the lung, liver and kidney tissues was significantly decreased in the diabetic group as compared with control group ($p<0.05$) (Fig. 2B). NAC treatment elevated total antioxidant activity in the lung and liver ($p<0.05$, D+NAC vs. D), but not in the kidney.

Total SOD activity in plasma and various tissues
The amount of SOD present in the cellular and extracellular environments is crucial for prevention of ROS mediated oxidative cellular damage. Plasma total SOD activity in the diabetic rats was much lower than that in the control group.
NADPH Oxidase Activation in Diabetic Rats

Yonsei Med J   http://www.eymj.org   Volume 53   Number 2   March 2012

...NADPH Oxidase Activation in Diabetic Rats

Yonsei Med J   http://www.eymj.org   Volume 53   Number 2   March 2012...

significantly in diabetic rats as compared to age-matched controls (all \( p < 0.05 \)) (Fig. 3B), and NAC treatment prevented the decrease in total SOD activity in the liver, but not in the kidney.

**Protein expression of Cu/Zn-SOD and Mn-SOD**

In the heart and lung tissues, the levels of Cu/Zn-SOD protein in the diabetic group increased significantly compared with controls (all \( p < 0.05 \), D vs. C) (Fig. 4A). NAC attenuated this increase in Cu/Zn-SOD protein expression in the heart (\( p < 0.05 \), D+NAC vs. D), but did not significantly affect Cu/Zn-SOD protein expression in the lung (Fig. 4A). In contrast, however, Cu/Zn-SOD protein expression in liver and kidney tissues in diabetic rats was lower than that of...
age-matched control rats ($p<0.05$ in liver, $p<0.01$ in kidney) (Fig. 4A). NAC prevented the decrease of Cu/Zn-SOD protein in the liver and attenuated its reduction in the kidney (all $p<0.05$, D+NAC vs. D) (Fig. 4A).

The changes of Mn-SOD protein expression in various tissues were different from those of Cu/Zn-SOD. There was no significant difference in Mn-SOD protein expression in the heart tissue among control, diabetic and NAC-treated diabetic groups (Fig. 4B). However, Mn-SOD protein expression in both the lung and the kidney decreased significantly in the diabetic group as compared to the control group, and NAC prevented the reduction of Mn-SOD protein in the lung ($p<0.05$, D+NAC vs. D) but further decreased its level in the kidney ($p<0.05$, D+NAC vs. D) (Fig. 4B). It is of an interest to note that Mn-SOD protein expression in the liver increased significantly in diabetic rats as compared control rats, but this increase was not affected by NAC treatment (Fig. 4B).

Expression of NADPH oxidase subunit: p22phox and p67phox

NADPH oxidase has been shown to be a major source of ROS production, and its subunits p22phox and p67phox are increased in the myocardium of STZ-induced diabetic rats. In the present study, we detected p22phox and p67phox protein expression in various tissues. As shown in Fig. 5A, p22phox protein levels in the heart, lung and kidney of the diabetic group were significantly higher than those of the control group, and NAC prevented the increase of p22phox protein expression in the lung, but did not normalize their increase in the heart and kidney (all $p<0.05$, D+NAC vs. D) (Fig. 5A). While there was no significant difference in p22phox protein expression in the liver between control and diabetic rats, 4 weeks of NAC treatment decreased its expression significantly ($p<0.05$, D+NAC vs. D or C) (Fig. 5A).

The p67phox protein expression was significantly increased both in the cytosol and membrane fractions in the lung, liver and kidney tissues of diabetic rats relative to control rats (Fig. 5B and C), reflecting increased p67phox activation as well as increased total protein levels which were in line with the increases of total p67phox protein expression in these tissues (data not shown). However, p67phox protein expression in the heart was significantly increased in the membrane fractions while markedly decreased in the cytosol fractions, reflecting increased p67phox activation. NAC prevented the increase of p67phox membrane translocation in the heart and liver and significantly attenuated the increase of p67phox membrane translocation in the lung and kidney tissues (all $p<0.05$, D+NAC vs. D) (Fig. 5C).

![Fig. 5. Western blot analysis of NADPH oxidase subunits p22phox and p67phox protein expression in various tissues. Control (C) or STZ-induced diabetic rats were either untreated (D) or treated with the antioxidant N-acetylcysteine (1.5 g/kg/day, D+NAC) by oral gavage for four weeks. (A) (top) Representative Western blot showing p22phox expression with GAPDH as a loading control in total tissue extracts; (bottom, graph) p22phox densitometric values were normalized to their corresponding GAPDH densitometric values and expressed as percent change relative to the measurement in control rats. (B) (top) Representative Western blot showing p67phox expression with Na,K-ATPase as a loading control in cytosol fractions; (bottom, graph) p67phox densitometric values were normalized to their corresponding GAPDH densitometric values and expressed as percent change relative to the measurement in control rats. (C) (top) Representative Western blot showing p67phox expression with Na,K-ATPase as a loading control in membrane fractions; (bottom, graph) p67phox densitometric values were normalized to their corresponding Na,K-ATPase densitometric values and expressed as percent change relative to the measurement in control rats. All the results are expressed as means±S.E.M., n=7, *$p<0.05$, **$p<0.01$ vs. C; †$p<0.05$ vs. D. NADPH, nicotinamide dinucleotide phosphate; STZ, streptozotocin.](http://www.eymj.org)
DISCUSSION

We have shown in the current study that the level of 15-F_{2t}-IsoP, a biomarker of oxidative stress, was elevated both in plasma and various tissues of type 1 diabetic rats. In contrast to reductions in total antioxidant activity in the lung, liver and kidney tissues, total antioxidant activity in the heart was elevated in the diabetic rats accompanied by an increase in heart tissue total SOD activity which indicated a significant up-regulation of self-defense mechanisms in the heart. The variations in SOD activity and protein expression in diabetes were tissue-specific. NAC treatment up-regulated Mn-SOD protein expression in diabetic rats in the lung tissue, but unexpectedly reduced Mn-SOD protein expression in the kidney. The underlying mechanisms governing the tissue-specific effects of NAC on SOD protein expression are not clear, nevertheless, it might be due to tissue-specific effectiveness of NAC in reducing the production of superoxide. Consequently, the organism may regulate the levels of SOD activation or protein expression on a basis of needs. It should be noted that NAC uniformly reduced the increase of p22phox protein expression and p67phox activation in all tissues studied, most likely inhibiting the activation of NADPH oxidase, a major source of ROS production in diabetes. This result is keeping with findings of a previous study which showed that NAC can inhibit NADPH oxidase activity in osteoblast precursor cells. Thus, our present studies together with others suggest that NAC can break vicious cycle of ROS-induced ROS production via NADPH oxidase activation in diabetes.

Increased oxidative stress can be the result of several diabetes-induced abnormalities, including auto-oxidation of glucose, the formation of advanced glycation end products, and impairment of defense system. The impaired defense system is always associated with reduced antioxidant capacity, abnormal activity or expression of antioxidant enzymes in diabetes. Among various antioxidant enzymes, SOD plays an important role in balancing ROS generation and the overall tissue antioxidant capacity. In our study, total antioxidant activity and SOD activity in the lung, liver and kidney tissues and total SOD activity in plasma were compromised in diabetic rats. It should be noted total antioxidant activity both in the plasma and heart tissues and total SOD activity in heart tissues were increased in diabetic rats, reflecting increased systemic antioxidant capacity overall and in the heart in particular. However, heart tissue level of 15-F_{2t}-isoprostane was increased despite these increases in systemic and heart tissue antioxidant activity. This indicates that up-regulation of antioxidant defenses is not sufficient to withstand hyperglycemia-induced increase in ROS production. It is also worth to note that in the control rats, the tissue total SOD activities in the heart and lung were much lower than those in the liver and kidney, which may suggest that SOD might not be the predominant endogenous antioxidant enzyme in the heart and lung in rats under physiological conditions. Other endogenous antioxidant enzymes such as glutathione peroxidase also play important roles in maintaining tissue antioxidant activity in these tissues under physiological conditions as well as in diabetes. Indeed, glutathione peroxidase and catalase are increased in the heart and lung of diabetic rats. This may explain the discrepancy between total antioxidant activity and SOD activity in plasma observed in the current study.

NADPH oxidase, a transmembrane enzyme located in intracellular organelles, is one of the major sources of ROS in diabetes. Recent studies show that the NADPH oxidase p22phox and gp91phox subunits were over-expressed in rat aorta, and that the p22phox, p47phox and p67phox subunits were increased in testes in STZ-induced diabetic rats. Our recent study shows that p22phox and p67phox, but not the p47phox, are robustly enhanced in the diabetic myocardium, and that NAC can prevent their increase. Therefore, in the current study, we specifically examined the changes of p22phox and p67phox in various tissues in diabetic rats, and found that p22phox and p67phox subunits were over-expressed or activated in various tissues in early diabetic rats, and that NAC treatment prevented or attenuated these changes in diabetes. NAC mediated reduction of p67phox translocation to membrane in various tissues was seen in the current study. This finding is in keeping with a previous study showing that NAC can inhibit NADPH oxidase activation. Thus, inhibition of NADPH oxidase over-expression and activation and the subsequent ROS production may represent a mechanism by which NAC reduces oxidative stress in diabetes in addition to its ROS scavenging property.

Mitochondrial dysfunction is another major intracellular source of ROS through the mitochondrial respiratory chain (MRC). About 4% of oxygen consumed in the mitochondria is converted to ROS. Impaired activities of enzymes in the MRC and mitochondrial DNA mutations were detected in patients with diabetes and in animal models of diabetes.

Mitochondrial derived superoxide anion is viewed as a sin-
gle unifying mechanism for diabetic complications.\textsuperscript{18,40} Over-expression of Mn-SOD, the major scavenger of mitochondrial superoxide anion, prevents high glucose-induced oxidative stress, cell apoptosis and mitochondrial DNA damage in retinal endothelial cells,\textsuperscript{19,20} and protects the retina from diabetes-induced oxidative stress in mice.\textsuperscript{41} In our present study, Mn-SOD expression in diabetic lung and kidney tissues decreased significantly, whereas Mn-SOD expression in diabetic liver tissue increased but was unchanged in heart tissue. This suggests that the change in mitochondrial SOD in response to hyperglycemia-induced oxidative stress is tissue-specific in early diabetes. NAC increased Mn-SOD in the lung, however, it did not increase it in the liver and further reduced its protein expression in the kidney, which might be the reason of why NAC could not bring down kidney tissue 15-F$_2$-IsoP content to a level comparable to that in the control rats.

Inflammation has been widely recognized as a key process of the progression of diabetes.\textsuperscript{42,43} Some inflammatory factors, such as TNF-alpha and IL-6, are elevated in patients with type 2 diabetes,\textsuperscript{44} and correlate with the incidence of diabetic macrovascular complications, especially atherosclerosis development.\textsuperscript{45} Our previous studies showed that long term (8 weeks) treatment with NAC attenuated myocardial levels of IL-6 protein expression and reduced plasma level of TNF-alpha in STZ induced diabetic rats.\textsuperscript{16,46} In the present study, we found that plasma levels of TNF-alpha and IL-6 were significantly increased in STZ-induced diabetic rats early at 4 weeks after the establishment of diabetes, and that NAC treatment for 4 weeks decreased the secretion of TNF-alpha and IL-6 cytokines, which reflects a suppression of inflammatory responses. Similar to our study, NAC has been demonstrated to have anti-inflammatory property both in vitro in lipopolysaccharide-activated macrophages\textsuperscript{47} and in vivo in humans.\textsuperscript{48}

In summary, the current study shows that oxidative stress occurs at an early stage of diabetes, and changes in the major pro-oxidant enzyme NADPH oxidase and the antioxidant enzyme SOD are tissue-specific in STZ-induced type 1 diabetic rats. Antioxidant NAC can confer protection against oxidative stress by suppressing NADPH oxidase activation and restoring or enhancing SOD enzyme activity and/or protein expression. The effects of NAC are tissue-specific, being more effective in the heart, lung and liver and less effective in the kidney. The current findings may have potential clinical implications in developing therapies for the treatment of diabetic complications.

\section*{ACKNOWLEDGEMENTS}

This is supported by grant 30872447 from the National Natural Science Foundation of China (NSFC) and General Research Fund grants 782910M from Research Grants Council of Hong Kong.

\section*{REFERENCES}

1. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1000-101.

2. Hakim FA, Pflueger A. Role of oxidative stress in diabetic kidney disease. Med Sci Monit 2010;16:RA37-48.

3. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1-9.

4. Ceriello A, Testa R. Antioxidant anti-inflammatory treatment in type 2 diabetes. Diabetes Care 2009;32 Suppl 2:S232-6.

5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.

6. Robinson I, de Serna DG, Gutierrez A, Schade DS. Vitamin E in humans: an explanation of clinical trial failure. Endocr Pract 2006;12:576-82.

7. Hasnain BI, Mooradian AD. Recent trials of antioxidant therapy: what should we be telling our patients? Cleve Clin J Med 2004;71:327-34.

8. Ristow M, Zarse K, Oberbach A, Klötting N, Birringer M, Kiehntopf M, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci U S A 2009;106:8665-70.

9. Gao L, Mann GE. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res 2009;82:9-20.

10. Shen GX. Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase. Can J Physiol Pharmacol 2010;88:241-8.

11. Lyle AN, Griendling KK. Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology (Bethesda) 2006;21:269-80.

12. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501.

13. Liu S, Ma X, Gong M, Shi L, Lincoln T, Wang S. Glucose down-regulation of cGMP-dependent protein kinase I expression in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species. Free Radic Biol Med 2007;42:852-63.

14. Li L, Renier G. Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered renal vascular endothelial growth factor expression. Metabolism 2006;55:1516-23.

15. Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res 2006;99:69-77.

16. Guo Z, Xia Z, Jiang J, McNeill JH. Downregulation of NADPH
oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine. Am J Physiol Heart Circ Physiol 2007;292:H1728-36.
17. Sandström J, Nilsson P, Karlsson K, Marklund SL. 10-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain. J Biol Chem 1994;269:19163-6.
18. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-25.
19. Kowlu ru RA, Atasi L, Ho YS. Role of mitochondrial superoxide dismutase in the development of diabetic retinopathy. Invest Ophthal Vis Sci 2006;47:1594-9.
20. Madsen-Bouterse SA, Zhong Q, Moh mad G, Ho YS, Kowlu ru RA. Oxidative damage of mitochondrial DNA in diabetes and its protection by manganese superoxide dismutase. Free Radic Res 2010;44:313-21.
21. Reis JS, Bosco AA, Veloso CA, Mattos RT, Purish S, Nogueira-Machado JA. Oxidizing and reducing responses in type 1 diabetic patients determined up to 5 years after the clinical onset of the disease. Acta Diabetol 2008;45:221-4.
22. Ivanović-Matić S, Mihailović M, Đinić S, Martinović V, Bogojević D, Grigorov I, et al. The absence of cardiomyopathy is accompanied by increased activities of CAT, MnSOD and GST in long-term diabetes in rats. J Physiol Sci 2010;60:259-66.
23. Ghosh S, Pulnilkumni T, Yuen G, Kewalramani G, An D, Qi D, et al. Cardiomyocyte apoptosis induced by short-term diabetes requires mitochondrial GSH depletion. Am J Physiol Heart Circ Physiol 2005;289:H768-76.
24. Yue KK, Chung WS, Leung AW, Cheng CH. Redox changes precede the occurrence of oxidative stress in eyes and aorta, but not in kidneys of diabetic rats. Life Sci 2003;73:2557-70.
25. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989;6:593-7.
26. Xia Z, Kuo KH, Nagareddy PR, Wang F, Guo Z, Guo T, et al. N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc Res 2007;73:770-82.
27. Meng X, Tancha roen S, Kawahara KI, Nawa Y, Taniguchi S, Hashiguchi T, et al. 1,5-Anhydroglucitol attenuates cytokine release and protects mice with type 2 diabetes from inflammatory reactions. Int J Immunopathol Pharmacol 2010;23:105-19.
28. Xu M, Dai DZ, Zhang Q, Cheng YS, Dai Y. Upregulated NADPH oxidase activity MrOxidase activation in diabetic rats. Exp Clin Endocrinol Diabetes 2010;118:459-65.
29. Wu HC, Wang Q, Yang HI, Alshan H, Tsai WY, Wang LY, et al. Urinary 15-F2t-isoprostane, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Carcino genesis 2008;29:971-6.
30. Faure P, Polge C, Monneret D, Favier A, Halimi S. Plasma 15-F2t isoprostane concentrations are increased during acute fructose loading in type 2 diabetes. Diabetes Metab 2008;34:148-54.
31. Mandal CC, Ganapathy S, Gorin Y, Mahadev K, Block K, Abbott HE, et al. Reactive oxygen species derived from Nox4 mediate BMP2 gene transcription and osteoblast differentiation. Bioch J 2011;433:393-402.
32. Wold LE, Ceylan-Isik AF, Ren J. Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta Pharmacol Sin 2005;26:908-17.
33. Du D, Shi YH, Le GW. Oxidative stress induced by high-glucose diet in liver of C57BL/6J mice and its underlying mechanism. Mol Biol Rep 2010;37:3833-9.
34. Ahmed FN, Naqvi FN, Shafiq F. Lipid peroxidation and serum antioxidant enzymes in patients with type 2 diabetes mellitus. Ann N Y Acad Sci 2006;1084:481-9.
35. Ramakrishna V, Jailkhani R. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol 2008;45:41-6.
36. Hünkar T, Aktan F, Ceylan A, Karasu C; Antioxidants in Diabetes-Induced Complications (ADIC) Study Group. Effects of cod liver oil on tissue antioxidant pathways in normal and streptozotocin-diabetic rats. Cell Biochem Funct 2002;20:297-302.
37. Okumura M, Ohran CE, Celenk FG, Ulker S. Apocynin restores endothelial dysfunction in streptozotocin diabetic rats through regulation of nitric oxide synthase and NADPH oxidase expression. J Diabetes Complications 2010;24:415-23.
38. Lenaz G, Bovina C, D’Aurelio M, Fato R, Formigini G, Genova ML, et al. Role of mitochondria in oxidative stress and aging. Ann N Y Acad Sci 2002;959:199-213.
39. Fosslien E. Mitochondrial medicine—molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci 2001;31:25-67.
40. Sack MN. Type 2 diabetes, mitochondrial biology and the heart. J Mol Cell Cardiol 2009;46:842-9.
41. Kowlu ru RA, Kowlur u V, Xiong Y, Ho YS. Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. Free Radic Biol Med 2006;41:1191-6.
42. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010;140:900-17.
43. Casas-Agu stench P, Bulló M, Salas-Salvadó J. Nuts, inflammation and insulin resistance. Asia Pac J Clin Nutr 2010;19:124-30.
44. Navarro-Gonzalez J, Morà-Fernandez C, Gomez-Chinchon M, Muros M, Herrera H, Garcia J. Serum and gene expression profile of tumor necrosis factor-alpha and interleukin-6 in hypertensive diabetic patients: effect of amiodipine administration. Int J Immunopharmacol 2010;23:61-9.
45. Wu W, Wang M, Sun Z, Wang X, Miao J, Zheng Z. The predictive value of TNF-alpha and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol 2010. [Epub ahead of print]
46. Tsai GY, Cui JZ, Syed H, Xia Z, Ozerdem U, McNeill JH, et al. Effect of N-acetylcysteine on the early expression of inflammatory markers in the retina and plasma of diabetic rats. Clin Experiment Ophthalmol 2009;37:223-31.
47. Palacio JR, Markert UR, Martinez P. Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages. Inflamm Res 2011;60:695-704.
48. Nascimento MM, Sultman ME, Silva M, Chinaglia T, Marchioro J, Hayashi SY, et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Pentr Dial Int 2010;30:336-42.